Clinical trials: Glucose Metabolism Disorders
Metabolic Syndrome, Obesity Hypoventilation Syndrome
Obesity-hypoventilation in Metabolic Syndrom Patients
The purpose of the study is to determined the prevalence of obesity-hypoventilation syndrome in patients with metabolic syndrom.
- Conditions
- Metabolic Syndrome, Obesity Hypoventilation Syndrome, Capnography
- Trial name
- NCT04839419
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- SOS Oxygene Mediterranee
Diabetes Mellitus Type 1
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.
- Trial name
- NCT01334151
- Testing
- Insulin LISPRO, recombinant human insulin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Biodel
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare FIAsp (faster-acting insulin aspart) to insulin aspart, both in combination with insulin glargine and metformin in adults with type 2…
- Trial name
- onset® 2 (NCT01819129)
- Testing
- Faster-acting insulin aspart, Insulin aspart, Insulin glargine
- Where
- 144 sites in United States, Canada and 8 more
- Volunteers
- 881 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT02933853
- Testing
- Faster-acting insulin aspart, Insulin Aspart
- Where
- Austria
- Volunteers
- 61 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00094757
- Testing
- Comparator: sitagliptin 100 mg, Comparator: sitagliptin 200 mg, Comparator: pioglitazone
- Volunteers
- 521 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.
- Trial name
- NCT00147719
- Testing
- Colesevelam hydrochloride
- Where
- 48 sites in United States, Mexico and 1 more
- Volunteers
- 300 people
- Sponsor
- Daiichi Sankyo
Diabetes
Diabetes Multicenter Observational Study (DIAMOND-1-)
The purpose of this study is to examine whether pump treatment combined with the use of continuous glucose monitoring system is a mena to normalize glycaemic control.
- Trial name
- DIAMOND-1 (NCT01369823)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medtronic Hellas Medical Devices ΑEE
Diabetes Mellitus, Type 2, Hypertension
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of…
- Trial name
- NCT01939496
- Testing
- Canagliflozin
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- Janssen Scientific Affairs, LLC
Type 2 Diabetes
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any…
- Trial name
- NCT00643851
- Testing
- Dapagliflozin, Metformin XR
- Where
- 99 sites in United States, Mexico and 5 more
- Volunteers
- 994 people
- Sponsor
- AstraZeneca
Healthy Volunteer, Type 2 Diabetes
A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477
This study is designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO6799477 following once daily oral administration for 2 weeks in healthy volunteers (Part 1) and in Type 2 diabetes…
- Trial name
- NCT02164266
- Testing
- RO6799477
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment…
- Trial name
- NCT00500331
- Testing
- GSK189075, pioglitazone
- Where
- 136 sites in United States, Argentina and 17 more
- Volunteers
- 334 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric…
- Trial name
- NCT02773381
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
The aim of this study is to assess how safe the study drug is and how well a participant tolerates it after a single oral (taken by mouth) dose.
- Trial name
- NCT03617081
- Testing
- NNC0113-2023
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin
The objectives of the study is to evaluate the efficacy and safety of DS-8500a compared with placebo in patients with type 2 diabetes mellitus (T2DM) receiving sitagliptin.
- Trial name
- NCT02685345
- Testing
- DS-8500a 25 mg, DS-8500a 75 mg
- Where
- Japan
- Volunteers
- 85 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
- Trial name
- NCT00268645
- Testing
- Insulin Glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 534 people
- Sponsor
- Sanofi
Albuminuria
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein…
- Trial name
- NCT00136773
- Testing
- amlodipine/benazepril
- Volunteers
- 332 people
- Sponsor
- Novartis
Chronic Kidney Disease
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.
- Trial name
- NCT02008851
- Testing
- Neo-kidney augment
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tengion
Obesity, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
- Trial name
- NCT06305351
- Testing
- K-757 and K-833 QD, K-757 and K-833 BID
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- TriGemX Bio, Inc.
Diabetes Mellitus, Type 2
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants…
- Trial name
- PIONEER START (NCT05444153)
- Testing
- Semaglutide, Empagliflozin
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes
This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this.
- Trial name
- NCT01159938
- Testing
- Lispro
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.